Доступ предоставлен для: Guest
Портал Begell Электронная Бибилиотека e-Книги Журналы Справочники и Сборники статей Коллекции
Critical Reviews™ in Oncogenesis
SJR: 0.631 SNIP: 0.503 CiteScore™: 2.2

ISSN Печать: 0893-9675
ISSN Онлайн: 2162-6448

Critical Reviews™ in Oncogenesis

DOI: 10.1615/CritRevOncog.v17.i4.30
pages 331-343

Current Status of Radiation Therapy for the Management of Rectal Cancer

William Rule
Department of Radiation Oncology, Mayo Clinic-Arizona, Phoenix, AZ
Jeffrey Meyer
Department of Radiation Oncology, University of Texas Southwestern, Dallas, TX

Краткое описание

Neoadjuvant chemoradiation for stage II and III rectal adenocarcinoma patients is delivered on a routine basis. This treatment paradigm, built on decades of clinical study, is continuously evolving. While multiple radiosensitizers have gained a great deal of interest over the past couple of decades, 5-fluorouracil still remains as the standard radiosensitizing agent. Long-course preoperative chemoradiotherapy is the current standard of care in the Unites States, but short-course hypofractionated preoperative radiotherapy is advocated by some investigators. This review will discuss the current standard of care in the preoperative setting for patients with rectal cancer and will also examine the novel ways in which investigators are modifying this regimen in an effort to improve patient outcomes.

Ключевые слова: rectal cancer, radiotherapy, chemoradiation

Articles with similar content:

Predictive Biomarkers for Response to Therapy in Advanced Colorectal/Rectal Adenocarcinoma
Critical Reviews™ in Oncogenesis, Vol.17, 2012, issue 4
Payal Kapur
Biology of Rectal Cancer−The Rationale for Targeted Therapy
Critical Reviews™ in Oncogenesis, Vol.17, 2012, issue 4
Sean Dineen
Twenty Years on: What Do We Really Know about Ewing Sarcoma and What Is the Path Forward?
Critical Reviews™ in Oncogenesis, Vol.20, 2015, issue 3-4
Elizabeth Lawlor, Poul H. Sorensen
Current Status of Radiosensitizing Agents for the Management of Rectal Cancer
Critical Reviews™ in Oncogenesis, Vol.17, 2012, issue 4
Henrik Illum
Venoms Can Be a Boon for Cancer Patients
Onco Therapeutics, Vol.4, 2013, issue 3-4
Sudhir Kumar, Ruchi Jain, Puja Sarkar